![Blocking PHGDH in tumors that overexpress it halts cell proliferation and cancer growth in vitro and in vivo. [© Arto - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/July14_2011_17369713_BreastCancerPinkRibbon_BreastCancerBresearchEnzyme1951905819-218x150.jpg "Regenerative Collagen Scaffold Offers Better Options for Reconstruction of Soft Tissue in Surgery")
Cellectis says the U.S. patent issued to the company this month will facilitate the development of future development of future T-cell immunotherapy treatments based on CRISPR-Cas . . .
Cellectis’ New Patent Supports CRISPR-Based T-Cell Immunotherapies
CEO Tells GEN Edge “Tech-Agnostic” Company Remains Committed to TALEN-Based Pipeline
T-cell medium for product candidate production. Cellectis says the U.S. patent issued to the company this month will facilitate the development of future T-cell immunotherapy treatments based on CRISPR-Cas. The company’s clinical-phase pipeline consists entirely of treatments that apply its proprietary TALEN® gene editing technology. [Cellectis]
